Alnylam Pharmaceuticals (HAM:DUL) Cyclically Adjusted Book per Share: €7.90 (As of Mar. 2026)


HAM:DUL Alnylam Pharmaceuticals Inc HAM:DUL
74 GF Score
Price €272.50
GF Value €452.87
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Cyclically Adjusted Book per Share?

Alnylam Pharmaceuticals HAM:DUL -0.55% 74 Cyclically Adjusted Book per Share is €7.90 as of Mar. 2026. GuruFocus rates HAM:DUL with a GF Score™ of 74/100 and a GF Value™ of €452.87 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €6.971. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Alnylam Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -12.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -3.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Alnylam Pharmaceuticals was 23.40% per year. The lowest was -9.70% per year. And the median was 10.90% per year.

As of today (2026-07-07), Alnylam Pharmaceuticals's current stock price is €272.50. Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €7.90. Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 34.49.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 49.35. The lowest was 4.66. And the median was 13.24.


Alnylam Pharmaceuticals  (HAM:DUL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=272.50/7.90
=34.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 49.35. The lowest was 4.66. And the median was 13.24.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.84 11.86 11.30 10.59 7.96

Alnylam Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.64 8.50 8.26 7.96 7.90

HAM:DUL vs RVMD, ONC, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


HAM:DUL
74GF Score
Alnylam Pharmaceuticals Inc HAM:DUL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.971/330.2130*330.2130
=6.971

Current CPI (Mar. 2026) = 330.2130.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 11.425 241.018 15.653
201609 10.544 241.428 14.422
201612 10.151 241.432 13.884
201703 9.026 243.801 12.225
201706 10.899 244.955 14.692
201709 9.618 246.819 12.868
201712 14.976 246.524 20.060
201803 14.165 249.554 18.743
201806 13.796 251.989 18.079
201809 12.546 252.439 16.411
201812 11.311 251.233 14.867
201903 12.867 254.202 16.714
201906 13.996 256.143 18.043
201909 13.108 256.759 16.858
201912 11.542 256.974 14.832
202003 10.794 258.115 13.809
202006 10.748 257.797 13.767
202009 8.882 260.280 11.268
202012 7.175 260.474 9.096
202103 6.631 264.877 8.267
202106 5.972 271.696 7.258
202109 5.378 274.310 6.474
202112 4.331 278.802 5.130
202203 3.017 287.504 3.465
202206 1.376 296.311 1.533
202209 -0.555 296.808 -0.617
202212 -1.205 296.797 -1.341
202303 -1.949 301.836 -2.132
202306 -3.016 305.109 -3.264
202309 -1.239 307.789 -1.329
202312 -1.608 306.746 -1.731
202403 -1.595 312.332 -1.686
202406 -0.022 314.175 -0.023
202409 0.226 315.301 0.237
202412 0.496 315.605 0.519
202503 0.819 319.799 0.846
202506 1.659 322.561 1.698
202509 1.512 324.800 1.537
202512 5.091 324.054 5.188
202603 6.971 330.213 6.971

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €7.90 mean?
Alnylam Pharmaceuticals (HAM:DUL) has a Cyclically Adjusted Book per Share of €7.90 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Alnylam Pharmaceuticals' current Cyclically Adjusted Book per Share is €7.90. Overall, Alnylam Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share compare to RVMD and ONC?
Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share of €7.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Cyclically Adjusted Book per Share is €7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (HAM:DUL) is currently considered Significantly Undervalued. The stock's GF Value™ is €452.87, compared to a current price of €272.50 — trading 39.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €7.90. Alnylam Pharmaceuticals' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Alnylam Pharmaceuticals (HAM:DUL), the current Cyclically Adjusted Book per Share is €7.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (HAM:DUL) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of €272.50 is trading 39.8% below its estimated GF Value™ of €452.87. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for HAM:DUL:

  • Cyclically Adjusted Book per Share: €7.90
  • GF Value™: €452.87 vs. price of €272.50 (39.8% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the HAM:DUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
74GF Score

Get the complete analysis for HAM:DUL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€272.50
Price
€452.87
GF Value